WO2003101427A8 - Immunoliposomes formed with aggregated antibody - Google Patents

Immunoliposomes formed with aggregated antibody

Info

Publication number
WO2003101427A8
WO2003101427A8 PCT/GB2003/002359 GB0302359W WO03101427A8 WO 2003101427 A8 WO2003101427 A8 WO 2003101427A8 GB 0302359 W GB0302359 W GB 0302359W WO 03101427 A8 WO03101427 A8 WO 03101427A8
Authority
WO
WIPO (PCT)
Prior art keywords
immunoliposomes
antibody
ligand
liposomes
aggregated antibody
Prior art date
Application number
PCT/GB2003/002359
Other languages
French (fr)
Other versions
WO2003101427A1 (en
Inventor
Andrew George
Peng Tan
Original Assignee
Imp College Innovations Ltd
Andrew George
Peng Tan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, Andrew George, Peng Tan filed Critical Imp College Innovations Ltd
Priority to AU2003241028A priority Critical patent/AU2003241028A1/en
Publication of WO2003101427A1 publication Critical patent/WO2003101427A1/en
Publication of WO2003101427A8 publication Critical patent/WO2003101427A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It has been found that aggregation of ligand-specific antibodies enhances their ablility to interact with liposomes in order to form ligand-specific immunoliposomes. The invention provides a process for the manufacture of immunoliposomes for targeting to a ligand of interest, comprising the step of : (a) treating a solution comprising antibody specific for ligand of interest, to give aggregated antibody; and (b) mixing the aggregated antibody with liposomes, thereby forming immunoliposomes. The process avoids the need for chemical modification of antibody and/or liposomes necessary for conjugation, it is rapid and it is simple.
PCT/GB2003/002359 2002-05-31 2003-05-30 Immunoliposomes formed with aggregated antibody WO2003101427A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003241028A AU2003241028A1 (en) 2002-05-31 2003-05-30 Immunoliposomes formed with aggregated antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212701.7A GB0212701D0 (en) 2002-05-31 2002-05-31 Immunoliposomes
GB0212701.7 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003101427A1 WO2003101427A1 (en) 2003-12-11
WO2003101427A8 true WO2003101427A8 (en) 2004-03-04

Family

ID=9937863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002359 WO2003101427A1 (en) 2002-05-31 2003-05-30 Immunoliposomes formed with aggregated antibody

Country Status (3)

Country Link
AU (1) AU2003241028A1 (en)
GB (1) GB0212701D0 (en)
WO (1) WO2003101427A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590411A (en) 2008-07-11 2013-07-26 Universal Biosensors Pty Ltd Enhanced immunoassay sensor
US20160298187A1 (en) * 2015-04-08 2016-10-13 Verily Life Sciences Llc Methods of tagging particles for multiplexed functional screening
IT201900007222A1 (en) 2019-05-24 2020-11-24 Univ Degli Studi Di Torino COMPOSITION OF LIPOSOMES AND METHOD OF DOSAGE BASED ON THE USE OF THE SAME

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
EP0759782A1 (en) * 1994-05-26 1997-03-05 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Also Published As

Publication number Publication date
GB0212701D0 (en) 2002-07-10
WO2003101427A1 (en) 2003-12-11
AU2003241028A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
MXPA03009785A (en) Vhh single heavy chain antibody and a method for its preparation in a mamal.
EP1741482A3 (en) Process and apparatus for producing microcapsules
WO2005012487A3 (en) Compositions and methods for preparing short rna molecules and other nucleic acids
IL172599A (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2001047959A3 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2003029458A3 (en) Method for producing protein libraries and for selecting proteins from said libraries
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
EP2289907A3 (en) Streptococcus agalactiae antigens I + II
WO2004093808A3 (en) Novel tumor-associated antigens
WO2007053181A3 (en) Chemically tailorable nanoparticles realized through metal-metalloligand coordination chemistry
WO2003101427A8 (en) Immunoliposomes formed with aggregated antibody
WO2004106385A3 (en) Monoclonal antibodies specific for buprenorphine and metabolites thereof
ATE435283T1 (en) ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER-ASSOCIATED ANTIGENS, THE ANTIGEN PER SE AND THEIR APPLICATIONS
WO2001005371A8 (en) Method for modifying physical and chemical and/or biological properties of a material
AU2001296830A1 (en) Ligand based solution assay for low concentration analytes
WO2005005632A3 (en) SMALL INTERFERING RNA SPECIFIC TO SUB-UNITS $G(A), $G(A)' AND $G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME
WO2003048729A3 (en) Discovery of therapeutic products
FI20021269A (en) A method for producing doped glass material
WO2002063010A3 (en) Method of producing recombinant antibodies against tumors
ATE360035T1 (en) FV CONSTRUCTS WITH INFLUENCABLE AFFINITY TO A SUBSTANCE TO BE BOUND
ZA200404571B (en) Filter, smoking articles containing the same, filter strands and methods and devices for producing filters and smoking articles of this type.
WO2004081027A3 (en) Neoplasm specific antibodies and uses thereof
WO2007095336A3 (en) Production of hiv
WO2002079297A3 (en) Coating material for electronic components
Archirel et al. On the R2PI spectrum of AgNH3: a theoretical study of the quasidegeneracy of the first excited states

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP